Stock Financial Ratios

PSDV / pSivida Corp. financial ratios include Market Cap, Enterprise Value, Book Value, Quick Ratio, Current Ratio, NCAV, EBITDA, Profit Margin, Operating Margin, Return on Invested Capital (ROIC), Return on Assets (ROA), Return on Equity (ROE), Piotroski F-Score, Altman Z-Score, Beneish M Score and Kaplan-Zingales KZ-Index.

Valuation Metrics
Market Cap ($M)47.71
Enterprise Value ($M)25.51
Book Value ($M)13.34
Book Value / Share0.38
Price / Book5.30
NCAV ($M)13.39
NCAV / Share0.38
Price / NCAV5.49
Income Statement (mra) ($M)
Net Income-18.48
Balance Sheet (mrq) ($M)
Cash & Equivalents11.83
Cash / Share0.33
Quick Ratio3.35
Current Ratio3.35
Management Effectiveness (mra)
Return on Invested Capital (ROIC)-1.39
Return on Assets (ROA)-0.99
Return on Equity (ROE)-1.39
Identifiers and Descriptors
Central Index Key (CIK)1314102
Industry Groups
SIC 3826 - Laboratory Analytical Instruments
Other Related CUSIPS
Share Statistics
Common Shares Outstanding (M)45.26
Scoring Models
Piotroski F Score2.00
Altman Z ScoreN/A
Beneish M ScoreN/A
Kaplan-Zingales KZ-IndexN/A
Cash Conversion CycleN/A
Per Share Metrics
Property Plant And Equipment Per Share0.01
Inventory Finished Goods Per Share0.00
Liabilities Other Non Current Per Share0.00
Intangibles Per Share0.00
Goodwill Per Share0.00
Accumulated Depreciation And Depletion Per Share0.00
Cash Per Share0.33
Liabilities And Stock Equity Per Share0.38
Equity Per Share0.25
Minority Interest Per Share0.00
Current Portion Of Long Term Debt Per Share0.00
Property Plant And Equipment Gross Per Share0.00
Accounts Receivable Per Share0.00
Assets Current Per Share0.35
Inventory Raw Materials Per Share0.00
Long Term Debt Per Share0.00
Treasury Stock Per Share0.00
Assets Other Current Per Share0.00
Assets Per Share0.38
Accounts Payable Per Share0.00
Property Plant And Equipment Net Per Share0.01
Preferred Stock Value Outstanding Per Share0.00
Assets Non Current Per Share0.00
Inventory Per Share0.00
Retained Earnings Per Share-8.96
Assets Other Non Current Per Share0.00
Additional Paid In Capital Per Share9.19
Liabilities Current Per Share0.12
Inventory Work In Progress Per Share0.00
Cash And Equivalents Per Share0.33
Liabilities Per Share0.12
Debt Per Share0.00
Deferred Income Tax Liabilities Per Share0.00

Stock Research Report

pSivida Corporation develop sustained-release drug delivery products that deliver drugs at a controlled and steady rate for months or years. pSivida hss developed three of the four sustained-release ophthalmic products currently approved by the U.S. FDA for treatment of back-of-the-eye diseases. Its product development programs are focused primarily on utilizing its core Durasert technology platform to deliver drugs to treat chronic diseases. Durasert three-year uveitis is its most advanced development-stage product, and is designed to treat chronic non-infectious uveitis affecting the posterior segment of the eye (posterior segment uveitis) for a period of three years. Durasert three-year uveitis met its primary efficacy endpoint of prevention of recurrence of uveitis through six months with a p value of < 0.001 in two ongoing pivotal Phase 3 clinical trials. pSivida anticipate filing an NDA with the FDA in late December 2017 or early January 2018. In July 2017, pSivida amended its co...

Click for full article

Related News Stories

pSivida's (PSDV) CEO Nancy Lurker on Q3 2017 Results - Earnings Call Transcript

2017-11-07 seekingalpha
Good day, ladies and gentlemen and welcome to the Q1 Fiscal 2018 pSivida Corporation Earnings Conference Call. At this time, all participants are in a listen-only mode. Later, we'll conduct a question-and-answer-session and instructions will follow at that time [Operator Instructions]. As a reminder, this conference is being recorded. (60-1)

pSivida: The Small Biotech With Big News Coming

2017-10-23 seekingalpha
At less than $47 million in market cap, pSivida is a sleeping giant with market disruptor technology. (51-14)

Biotech Stocks Ignite in the News on Tuesday

2017-10-10 accesswire
CORAL GABLES, FL / ACCESSWIRE / October 10, 2017 / Here are two biotech stocks to watch after both companies released news on Tuesday pre-market: (45-0)

Your Daily Pharma Scoop: Celgene's CELMoD Potential, Allergan's Senate Troubles, Abbott Approval Surge

2017-09-28 seekingalpha
This abridged “Daily Scoop” is published by Avisol Capital Partners, which runs the physician-managed Total Pharma Tracker healthcare investment research service on Seeking Alpha Marketplace. (611-8)

CUSIP: 74440J101